308 related articles for article (PubMed ID: 33485320)
1. Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study.
Oshima Y; Ishibashi Y; Umeda N; Nagata T; Yoshida S; Uchio E; Kondo H; Sonoda KH; Ishibashi T
BMC Ophthalmol; 2021 Jan; 21(1):58. PubMed ID: 33485320
[TBL] [Abstract][Full Text] [Related]
2. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration.
Zhu M; Wijeyakumar W; Syed AR; Joachim N; Hong T; Broadhead GK; Li H; Luo K; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):475-484. PubMed ID: 27572301
[TBL] [Abstract][Full Text] [Related]
3. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.
Yuzawa M; Fujita K; Wittrup-Jensen KU; Norenberg C; Zeitz O; Adachi K; Wang EC; Heier J; Kaiser P; Chong V; Korobelnik JF
Ophthalmology; 2015 Mar; 122(3):571-8. PubMed ID: 25439429
[TBL] [Abstract][Full Text] [Related]
4. Single-site Baseline and Short-term Outcomes of Clinical Characteristics and Life Quality Evaluation of Chinese Wet Age-related Macular Degeneration Patients in Routine Clinical Practice.
Wang LL; Liu WJ; Liu HY; Xu X
Chin Med J (Engl); 2015 May; 128(9):1154-9. PubMed ID: 25947396
[TBL] [Abstract][Full Text] [Related]
5. Vision-related quality of life in Japanese patients with wet age-related macular degeneration treated with intravitreal aflibercept in a real-world setting.
Gomi F; Migita H; Sakaguchi T; Okada H; Sugawara T; Hikichi Y;
Jpn J Ophthalmol; 2019 Nov; 63(6):437-447. PubMed ID: 31673841
[TBL] [Abstract][Full Text] [Related]
6. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
Wada I; Oshima Y; Shiose S; Kano K; Nakao S; Kaizu Y; Yoshida S; Ishibashi T; Sonoda KH
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
[TBL] [Abstract][Full Text] [Related]
7. The effects of loading ranibizumab on vision-related quality of life in the treatment of low-risk neovascular age-related macular degeneration.
Daldal H
Ther Adv Ophthalmol; 2022; 14():25158414221108021. PubMed ID: 35873278
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Ranibizumab Loading Treatment on Vision-Related Quality of Life in Diabetic Macular Edema.
Daldal H; Turkyilmaz M; Balikoglu Yilmaz M; Berberoglu U
Clin Pract; 2021 Sep; 11(3):659-670. PubMed ID: 34563010
[TBL] [Abstract][Full Text] [Related]
9. Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration.
Stoller GL; Kokame GT; Dreyer RF; Shapiro H; Tuomi LL
JAMA Ophthalmol; 2016 May; 134(5):545-553. PubMed ID: 27010625
[TBL] [Abstract][Full Text] [Related]
10. The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration.
Inan S; Polat O; Karadas M; Inan UU
Rom J Ophthalmol; 2019; 63(3):238-244. PubMed ID: 31687625
[No Abstract] [Full Text] [Related]
11. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany.
Finger RP; Wiedemann P; Blumhagen F; Pohl K; Holz FG
Acta Ophthalmol; 2013 Sep; 91(6):540-6. PubMed ID: 23171290
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research.
Wolf A; Kampik A
Graefes Arch Clin Exp Ophthalmol; 2014 Apr; 252(4):647-55. PubMed ID: 24424409
[TBL] [Abstract][Full Text] [Related]
13. Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study.
Kertes PJ; Galic IJ; Greve M; Williams RG; Rampakakis E; Scarino A; Sheidow T
Ophthalmology; 2019 Jun; 126(6):841-848. PubMed ID: 30677465
[TBL] [Abstract][Full Text] [Related]
14. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P;
Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
[TBL] [Abstract][Full Text] [Related]
15. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Brown DM; Chen E; Mariani A; Major JC;
Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration.
Inoue M; Yamane S; Sato S; Sakamaki K; Arakawa A; Kadonosono K
Am J Ophthalmol; 2016 Sep; 169():95-103. PubMed ID: 27320059
[TBL] [Abstract][Full Text] [Related]
17. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL
JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617
[TBL] [Abstract][Full Text] [Related]
18. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials.
Suñer IJ; Kokame GT; Yu E; Ward J; Dolan C; Bressler NM
Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3629-35. PubMed ID: 19255158
[TBL] [Abstract][Full Text] [Related]
19. Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration - results from the randomized, phase IIIb OCTAVE study.
Staurenghi G; Garweg JG; Gerendas BS; Macfadden W; Gekkiev B; Margaron P; Dunger-Baldauf C; Kolar P
BMC Ophthalmol; 2020 Jan; 20(1):18. PubMed ID: 31918685
[TBL] [Abstract][Full Text] [Related]
20. Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study).
Bhisitkul RB; Desai SJ; Boyer DS; Sadda SR; Zhang K
Ophthalmology; 2016 Jun; 123(6):1269-77. PubMed ID: 26996339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
